NASDAQ:CRON - Cronos Group Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.80
  • Forecasted Upside: 23.08 %
  • Number of Analysts: 6
  • Breakdown:
  • 3 Sell Ratings
  • 2 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.08 (-1.11%)

This chart shows the closing price for CRON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cronos Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRON

Analyst Price Target is $8.80
▲ +23.08% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Cronos Group in the last 3 months. The average price target is $8.80, with a high forecast of $12.50 and a low forecast of $5.00. The average price target represents a 23.08% upside from the last price of $7.15.

This chart shows the closing price for CRON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Cronos Group. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 3 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 3 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 3 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 3 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/15/2021Raymond JamesSet Price TargetOutperform$11.00Low
6/7/2021Raymond JamesReiterated RatingOutperform$11.00Low
5/10/2021Raymond JamesSet Price TargetOutperform$11.00Low
4/28/2021Bank of AmericaInitiated CoverageUnderperformHigh
4/26/2021Raymond JamesSet Price TargetOutperform$11.00Low
3/1/2021Raymond JamesSet Price TargetOutperform$11.00Low
3/1/2021Canaccord GenuityBoost Price TargetSell$6.50 ➝ $7.50Low
2/22/2021CIBCDowngradeOutperform ➝ Neutral$8.00 ➝ $12.50Low
2/4/2021Stifel NicolausReiterated RatingHold$8.00Low
11/17/2020Raymond JamesBoost Price TargetOutperform$10.00 ➝ $11.00Low
11/16/2020Jefferies Financial GroupLower Price TargetUnderperform$5.60 ➝ $5.00Low
11/6/2020Raymond JamesSet Price TargetOutperform$10.00High
9/14/2020Raymond JamesSet Price TargetOutperform$10.00High
9/8/2020Raymond JamesSet Price TargetOutperform$10.00Medium
9/2/2020Raymond JamesSet Price TargetOutperform$10.00High
8/18/2020Raymond JamesSet Price TargetOutperform$10.00Low
8/7/2020Raymond JamesSet Price TargetOutperform$10.00N/A
6/23/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$6.50 ➝ $13.52High
5/22/2020Raymond JamesSet Price TargetMarket Perform$6.50Medium
5/11/2020Pi FinancialReiterated RatingHold$8.50Medium
5/11/2020Raymond JamesSet Price TargetMarket Perform$6.50Low
5/11/2020Canaccord GenuityReiterated RatingSell$6.50High
5/11/2020Stifel NicolausLower Price TargetHold$8.00 ➝ $7.50High
4/27/2020Raymond JamesDowngradeOutperform ➝ Market Perform$10.50 ➝ $6.50High
4/19/2020Piper SandlerDowngradeOverweight ➝ NeutralMedium
4/13/2020Piper SandlerDowngradeOverweight ➝ Neutral$12.00 ➝ $7.00High
4/2/2020Bank of AmericaDowngradeBuy ➝ Neutral$9.00Low
3/31/2020Canaccord GenuityDowngradeHold ➝ SellHigh
3/4/2020MKM PartnersUpgradeNeutral ➝ Buy$12.00 ➝ $11.00High
3/3/2020Stifel NicolausDowngradeBuy ➝ Hold$12.00 ➝ $8.00High
12/21/2019Raymond JamesSet Price TargetOutperform$12.00Low
11/13/2019CIBCReiterated RatingBuy$17.00High
10/22/2019Piper Jaffray CompaniesLower Price TargetOverweight$18.00 ➝ $12.00Low
10/18/2019Stifel NicolausUpgradeHold ➝ Buy$16.50 ➝ $14.00High
9/19/2019MKM PartnersInitiated CoverageNeutral$14.00Low
9/5/2019BMO Capital MarketsUpgradeUnderperform ➝ Market PerformHigh
8/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$18.00Medium
8/9/2019BMO Capital MarketsReiterated RatingSellMedium
8/9/2019Bank of AmericaBoost Price TargetBuy$20.00 ➝ $26.00Low
8/9/2019Canaccord GenuityUpgradeSell ➝ Hold$16.00 ➝ $17.00High
6/28/2019Consumer EdgeInitiated CoverageEqual Weight ➝ Equal WeightLow
6/5/2019Stifel NicolausInitiated CoverageHold ➝ HoldLow
6/5/2019Bank of AmericaUpgradeUnderperform ➝ Buy$13.00 ➝ $20.00High
4/17/2019Bank of AmericaInitiated CoverageUnderperform ➝ Underperform$13.00Medium
3/27/2019CIBCSet Price TargetBuy$30.00Low
3/27/2019Canaccord GenuityDowngradeHold ➝ Sell$17.00High
3/26/2019Pi FinancialReiterated RatingBuy ➝ Neutral$24.00High
3/11/2019BMO Capital MarketsDowngradeMarket Perform ➝ Underperform$21.43Low
3/7/2019Eight CapitalDowngradeHoldLow
3/5/2019CowenInitiated CoverageMarket PerformHigh
2/25/2019Jefferies Financial GroupInitiated CoverageUnderperform ➝ UnderperformHigh
2/5/2019GMP SecuritiesDowngradeBuy ➝ HoldHigh
1/18/2019CIBCInitiated CoverageSector Outperform ➝ Sector OutperformHigh
11/19/2018GMP SecuritiesReiterated RatingBuyMedium
11/15/2018Canaccord GenuityReiterated RatingHold ➝ Average$9.00Low
8/15/2018Canaccord GenuityUpgradeSell ➝ HoldHigh
5/4/2018Beacon SecuritiesReiterated RatingBuyLow
5/1/2018Canaccord GenuityDowngradeHold ➝ SellHigh
4/6/2018GMP SecuritiesUpgradeHold ➝ BuyHigh
(Data available from 7/23/2016 forward)
Cronos Group logo
Cronos Group Inc. operates as a cannabinoid company. It manufactures, markets, and distributes hemp-derived supplements and cosmetic products through e-commerce, retail, and hospitality partner channels under the Lord Jones and Happy Dance brands in the United States. The company is also involved in the cultivation, manufacture, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. It sells cannabis and cannabis products, including dried cannabis, pre-rolls, and cannabis extracts through wholesale and direct-to-client channels under its wellness platform, PEACE NATURALS; and operates under two adult-use brands, COVE and Spinach. The company also exports dried cannabis and cannabis oils to Germany, Israel, and Australia. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Read More

Today's Range

Now: $7.15
Low: $7.05
High: $7.25

50 Day Range

MA: $8.20
Low: $7.15
High: $9.06

52 Week Range

Now: $7.15
Low: $4.91
High: $15.83


865,739 shs

Average Volume

4,233,179 shs

Market Capitalization

$2.66 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Cronos Group?

The following equities research analysts have issued stock ratings on Cronos Group in the last twelve months: Bank of America Co., Canaccord Genuity, CIBC, Jefferies Financial Group Inc., Raymond James, Stifel Nicolaus, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CRON.

What is the current price target for Cronos Group?

5 Wall Street analysts have set twelve-month price targets for Cronos Group in the last year. Their average twelve-month price target is $8.80, suggesting a possible upside of 21.7%. CIBC has the highest price target set, predicting CRON will reach $12.50 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $5.00 for Cronos Group in the next year.
View the latest price targets for CRON.

What is the current consensus analyst rating for Cronos Group?

Cronos Group currently has 3 sell ratings, 2 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRON, but not buy more shares or sell existing shares.
View the latest ratings for CRON.

What other companies compete with Cronos Group?

How do I contact Cronos Group's investor relations team?

Cronos Group's physical mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The company's listed phone number is 416-504-0004. The official website for Cronos Group is